Raymond James & Associates acquired a new position in Accelerate Diagnostics, Inc. (NASDAQ:AXDX – Get Rating) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 17,499 shares of the medical research company's stock, valued at approximately $27,000.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in AXDX. Bank of Montreal Can acquired a new stake in shares of Accelerate Diagnostics during the 1st quarter worth approximately $27,000. UBS Group AG grew its holdings in Accelerate Diagnostics by 1,004.2% during the 2nd quarter. UBS Group AG now owns 43,593 shares of the medical research company's stock worth $44,000 after acquiring an additional 39,645 shares during the period. HighTower Advisors LLC raised its position in shares of Accelerate Diagnostics by 115.6% during the 1st quarter. HighTower Advisors LLC now owns 37,302 shares of the medical research company's stock valued at $53,000 after acquiring an additional 20,000 shares during the last quarter. Chartist Inc. CA bought a new stake in shares of Accelerate Diagnostics during the 2nd quarter valued at $65,000. Finally, Price T Rowe Associates Inc. MD lifted its stake in shares of Accelerate Diagnostics by 102.7% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 90,280 shares of the medical research company's stock valued at $90,000 after purchasing an additional 45,731 shares during the period. 33.14% of the stock is currently owned by institutional investors and hedge funds.
Get Accelerate Diagnostics alerts:Wall Street Analysts Forecast Growth
Separately, StockNews.com raised Accelerate Diagnostics from a "sell" rating to a "hold" rating in a research note on Thursday, February 2nd.
Accelerate Diagnostics Stock Performance
Shares of NASDAQ:AXDX opened at $0.67 on Thursday. The company has a 50 day moving average price of $0.68 and a two-hundred day moving average price of $1.25. The company has a market capitalization of $54.64 million, a PE ratio of -0.70 and a beta of 1.09. Accelerate Diagnostics, Inc. has a 52 week low of $0.46 and a 52 week high of $3.74.Accelerate Diagnostics (NASDAQ:AXDX – Get Rating) last released its quarterly earnings data on Monday, November 14th. The medical research company reported ($0.18) EPS for the quarter, beating analysts' consensus estimates of ($0.21) by $0.03. The firm had revenue of $2.96 million during the quarter, compared to the consensus estimate of $3.50 million. On average, sell-side analysts forecast that Accelerate Diagnostics, Inc. will post -0.86 earnings per share for the current year.
Accelerate Diagnostics Profile
(Get Rating)
Accelerate Diagnostics, Inc is an in vitro diagnostics company, which engages in the provision of solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. It also focuses on developing and commercializing innovative instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens.
Featured Articles
- Get a free copy of the StockNews.com research report on Accelerate Diagnostics (AXDX)
- CVS Health Corporation Is Coiled And Ready To Spring Higher
- Will The Pullback In Paycom Payoff For Investors?
- TJX Among Apparel Retailers All Dressed Up & Ready For Growth
- Daqo New Energy Charged Up For New Highs
- No Spice In Chipotle Results, Is Now The Time To Buy?
Want to see what other hedge funds are holding AXDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Accelerate Diagnostics, Inc. (NASDAQ:AXDX – Get Rating).
Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.